Medical technology is advancing at an increasingly rapid pace. At no other time in history have we seen such remarkable advancements in the treatment of disease in such short amounts of time. At the forefront of this development is Amicus Therapeutics, a biotechnology company that specializes in the development of therapies for rare and orphan diseases.
Amicus Therapeutics, founded in 2002, went public in 2007. Since then, the company has developed technology for countless different ailments. Their leading product, migalastat, is used to treat individuals with Fabry disease. Another product of theirs, SD-101, was developed to combat an extremely rare genetic connective tissue disorder, Epidermolysis Bullosa. SD-101 has the added distinction of potentially being the first treatment on the market.
While these developments are extremely impressive in their own right, Amicus Therapeutics has distinguished themselves even further. In 2005, the company was issued a five hundred thousand dollar grant by the Micheal J. Fox Foundation for their research. With the grant, the company conducted several years of research in coordination with UCLA. In that same year, they were awarded another grant for two hundred thousand dollars for developments in Alzheimer’s treatments by the Alzheimer’s Disease Research Center.
Amicus Therapeutics is a research center with a strong commitment to their patients and investors. By their own words, they seek to deliver the highest quality of living for any person suffering from the diseases they seek to treat. They aim to make their own cutting edge technologies obsolete at a shockingly fast pace. This earnest attitude extends to their prospects as a business. Whilst intensely focused on their aspirations as a developer of biotechnologies, Amicus Therapeutics aims to be business minded in terms of longevity. Intent on making strategic partnerships and pricing their products fairly, they have their eyes on the future as much as they do the present.
Biotechnology will continue to move at a blinding pace in the coming years. As such, whether one is viewing Amicus Therapeutics as a patient or a business partner, they can rest easy knowing the latest and greatest in medical technology won’t pass them by.